Increasing demand for immunoglobin driving the global blood plasma products market
Categorized as “rare diseases,” primary immunodeficiency diseases are typically hereditary and genetic disorders of the body’s immunity, which is partially or totally missing or does not function properly. These deficiencies make the human body vulnerable to a wide range of infections that affect different parts of the body like the lungs, intestines, skin, ears, and others, and are generally chronic, persistent, and debilitating. Primary immunodeficiency diseases are a universally accepted indication for immunoglobin therapy, which is a life-saving treatment for a majority of people with immunodeficiency as it offers protection against infections and reduces autoimmune symptoms. Immunoglobin therapies have significantly improved the quality of life of people with immunodeficiency, many of which can now live normal lives.
Importance of immunoglobin for treating immunodeficiency diseases
Immunoglobulin has been around for a long time as replacement therapy in primary immune deficiency. Immunoglobin administration has emerged as the primary treatment for the immunocompromised patient and has recently expanded for treating patients with an inflammatory disease and autoimmune neuropathies as per the established clinical guidelines. Moreover, evidence-based clinical indications for the use of immunoglobin also include idiopathic thrombocytopenic purpura, B-cell chronic lymphocytic leukemia, Kawasaki disease, chronic idiopathic demyelinating polyneuropathy, multifocal motor neuropathy, bone marrow transplantation, and pediatric HIV infection, among others, which have evolved over time. Immunoglobin replacement is also indicated for patients who suffer from recurring bacterial infections and reduced serum immunoglobin levels along with failing to respond to a protein or polysaccharide vaccine challenge.
Immunoglobulins are essentially antibodies produced by differentiated B cells called plasma cells. Immunoglobin is primarily responsible for the growing prominence of the global blood plasma products market. The immunoglobin molecule has a distinctive structure which provides the ability to recognize specific antigenic determinants. Immunoglobin formulations are produced from the pooled human plasma of thousands of healthy donors, which allows the immunoglobin formulations to contain a large and diverse range of antibodies. It goes without saying that the supply of immunoglobin is finite because it depends on donated plasma.
Immunoglobulin has been used for therapy in a number of autoimmune disorders, although efficacy in this area is still under observation. Complicating factors exist because this category includes several different autoimmune diseases (eg, hematologic, neurologic, organ-specific) and the treatment approach to these diseases has markedly changed and advanced with the introduction of biologic and immunomodulation drugs for therapy.
Growing importance of immunoglobin holds the market for blood plasma in good stead
The increasing demand of immunoglobulin for the treatment of immunodeficiency drive the market growth. Rise in technology at plasma collection centers to collect plasma and record patient history, and use of dried plasma that reduced cold chain requirements are the major trends in the market, which is poised to witness a CAGR of 6.8% to reach USD 28.5 Bn in 2023, according to Research On Global Markets. Among the different products in the market, immunoglobulin has the highest market share (approximately 47%) because of the growing incidence of immunological diseases across the world coupled with the rise in the geriatric population.